title: Oral administration of aprepitant to prevent postoperative nausea in highly susceptible patients after gynecological laparoscopy.
abstract: OBJECTIVE
  The use of opioids following surgery is associated with a high incidence of postoperative nausea and vomiting (PONV). We conducted a prospective, randomized, double-blind, placebo-controlled study to investigate the effect of orally administered aprepitant, a neurokinin-1 receptor antagonist, for reducing PONV in patients with fentanyl-based, patient-controlled analgesia (PCA) given intravenously after gynecological laparoscopy.
  
  
  METHODS
  One hundred and twenty female patients (ages 21-60) undergoing laparoscopic hysterectomy were randomly allocated to receive 80 mg (A80 group, n = 40) or 125 mg aprepitant (A125 group, n = 40) or placebo (control group, n = 40) orally 2 h before anesthesia induction. Anesthesia was maintained with isoflurane and remifentanil, and PCA IV using fentanyl and ketorolac were provided for 48 h after surgery. Incidences of nausea, vomiting/retching, and use of rescue antiemetics were recorded at 2, 24, and 48 h after surgery. Complete response was defined as no PONV and no need for rescue treatment.
  
  
  RESULTS
  The incidence of complete response was significantly lower in the A80 and A125 groups than in controls, 56 % and 63 %, vs. 28 %, respectively, P = 0.007 and P = 0.003, respectively, during the first 48 h, and 65 % and 65 % vs. 38 %, respectively, both P = 0.025, during the first 2 h. However, there were no statistically significant differences between A80 and A125 groups in the incidences of complete response and PONV during the study period.
  
  
  CONCLUSIONS
  Aprepitant 80 mg orally was effective in lowering the incidence of PONV in the first 48 h after anesthesia in patients receiving fentanyl-based PCA after gynecological laparoscopy.
authors.affiliation: Department of Anesthesiology and Pain Medicine, Gil Medical Center, Gachon University, Inchon, South Korea.
authors.forename: Wol Seon
authors.initials: WS
authors.lastname: Jung
authors.forename: Yong Beom
authors.initials: YB
authors.lastname: Kim
authors.forename: Hee Yeon
authors.initials: HY
authors.lastname: Park
authors.forename: Woo Jong
authors.initials: WJ
authors.lastname: Choi
authors.forename: Hong Seuk
authors.initials: HS
authors.lastname: Yang
mesh_terms: D000284:Administration, Oral; D016058:Analgesia, Patient-Controlled / Q000379:methods; D000932:Antiemetics / Q000627:therapeutic use*; D000077608:Aprepitant; D004311:Double-Blind Method; D005260:Female; D005283:Fentanyl / Q000627:therapeutic use; D013509:Gynecologic Surgical Procedures / Q000379:methods*; D006801:Humans; D007275:Injections, Intravenous / Q000379:methods; D010535:Laparoscopy / Q000379:methods; D008875:Middle Aged; D009025:Morpholines / Q000008:administration & dosage*; D064729:Neurokinin-1 Receptor Antagonists / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000517:prevention & control; D020250:Postoperative Nausea and Vomiting / Q000517:prevention & control*; D011446:Prospective Studies; D014839:Vomiting / Q000517:prevention & control
chemical_list: D000932:Antiemetics; D009025:Morpholines; D064729:Neurokinin-1 Receptor Antagonists; D000077608:Aprepitant; D005283:Fentanyl